Morpholino Oligonucleotides

Morpholino Oligonucleotides is a synthetic antisense oligonucleotide analog that belongs to the class of nucleic acid derivatives in which the ribose sugar is replaced by a morpholine ring and phosphodiester linkages are replaced by phosphorodiamidate groups, enabling sequence-specific gene expression modulation through steric blocking of RNA targets without inducing RNase H degradation.

714

Publications

49.6K

Citations

3.2K

Authors

853

Institutions

Publications per year

2017–2026

121

Variants

Morpholinos

Parents

Oligonucleotide Chemistry

Publications

714

U1 snRNP regulates cancer cell migration and invasion in vitro

Jung‐Min Oh, Christopher C. Venters, Chao Di et al. · Nature Communications · 2020 · 7.2K citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Sebahattin Çirak, Virginia Arechavala‐Gomeza, Michela Guglieri et al. · The Lancet · 2011 · 862 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Polymer support oligonucleotide synthesis XVIII<sup>1.2)</sup>: use of<i>β</i>-cyanoethyi-N,N-dialkylamino-/N-morpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection and isolation of the final product

N. D. SINHA, J. Biernat, J. F. A. McManus et al. · Nucleic Acids Research · 1984 · 848 citations · Full text

Pharmacy, Biotechnology, Molecular Biology +16

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

Maria Kinali, Virginia Arechavala‐Gomeza, Lucy Feng et al. · The Lancet Neurology · 2009 · 639 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology

J. Alter, Fang Lou, Adam Rabinowitz et al. · Nature Medicine · 2006 · 492 citations

Pharmacy, Molecular Medicine, Neuroscience +16

1–5 of 714

Authors

3.2K

PL
Patrick L. Iversen
Sarepta Therapeutics (United States), United States
63 publications · 4.6K citations
45
h-index
DA
David A. Stein
Sarepta Therapeutics (United States), United States
33 publications · 2.2K citations
26
h-index
HM
Hong M. Moulton
Oregon State University, United States
30 publications · 2.7K citations
23
h-index
MJ
Matthew J. A. Wood
University of Oxford, United Kingdom
16 publications · 2.7K citations
16
h-index
SD
Steve D. Wilton
The University of Western Australia, Australia
17 publications · 2.9K citations
16
h-index

1–5 of 3.2K

Institutions

853

1–8 of 853

Venues

Development
49 publications · 5.2K citations
41
h-index
PLoS ONE
33 publications · 1.3K citations
22
h-index
Molecular Therapy
21 publications · 1.4K citations
20
h-index
Developmental Dynamics
29 publications · 1.3K citations
20
h-index
Proceedings of the National Academy of Sciences
PNAS · 16 publications · 1.7K citations
16
h-index

1–5